Targeting Janus kinases in the treatment of autoimmune disease

Key Takeaways for GI Nurses

• Janus kinase (JAK) inhibitors are increasingly relevant in GI practice because JAK3 and related pathways drive cytokine signaling implicated in inflammatory bowel disease (IBD), meaning more of your IBD patients may be prescribed these oral small-molecule agents.
• Understanding that JAK inhibitors work by blocking intracellular cytokine signaling (rather than neutralizing cytokines directly, as biologics do) helps nurses better educate patients about how these medications differ from anti-TNF or anti-integrin therapies.
• Patients on JAK inhibitors require specific pre-procedure and periprocedural considerations, including infection risk screening, medication timing around endoscopy, and awareness of potential immunosuppression when planning bowel prep, sedation, and biopsy protocols.
• As this drug class expands across multiple autoimmune conditions (IBD, psoriasis, rheumatoid arthritis), GI nurses will increasingly encounter patients with overlapping autoimmune diagnoses, requiring coordinated care with rheumatology and dermatology teams.

Clinical Relevance

This research summary highlights foundational science behind JAK3 discovery and its link to immune regulation—work that has directly enabled development of JAK inhibitors now used in IBD management, including ulcerative colitis. For endoscopy and GI nurses, this translates into practical, everyday relevance: patients arriving for surveillance colonoscopies, flare evaluations, or biologic-failure workups may be on or being considered for JAK inhibitor therapy (e.g., tofacitinib, upadacitinib). Recognizing these medications on a patient's history and understanding their mechanism—blocking intracellular signaling for cytokines like IL-2, IL-7, IL-15, and IL-21—allows nurses to ask more informed questions during pre-procedure assessments, particularly regarding infection history, herpes zoster risk, and recent lab work (lipid panels, CBC, LFTs) that prescribers monitor.

From an operational standpoint, units should ensure intake questionnaires and EHR medication reconciliation clearly capture JAK inhibitor use, since these drugs carry FDA boxed warnings for serious infections, malignancy, and thrombosis risk. Nurses coordinating procedural scheduling may need to liaise with prescribing gastroenterologists or rheumatologists regarding whether to hold doses periprocedurally, especially if biopsies or polypectomies increase bleeding or infection risk. Additionally, as this therapeutic class expands beyond IBD into psoriasis, psoriatic arthritis, alopecia areata, and other autoimmune diseases, endoscopy nurses will likely see more complex, multi-morbid patients requiring careful chart review and interdisciplinary communication.

Professionally, this underscores the value of continuing education on immunomodulatory and biologic therapies. As GI nursing increasingly intersects with immunology-driven treatment paradigms, staying current on drug mechanisms—even those originating from basic science patents and pharma collaborations like the CRADA referenced here—equips nurses to anticipate side effects, answer patient questions accurately, and contribute meaningfully to multidisciplinary IBD care teams.

Bottom Line

JAK inhibitors, grounded in the JAK3 discovery highlighted in this research, are an expanding therapeutic class relevant to IBD and other autoimmune conditions seen in GI practice; endoscopy nurses should be prepared to recognize these medications during patient intake, understand their infection and safety monitoring requirements, and coordinate periprocedural care accordingly.